-
Mashup Score: 7
ASTRO 2023, Prostate cancer, Oligometastatic Castration-Sensitive Prostate Cancer PSMA-Positive Extracellular Vesicles, Stereotactic Ablative Radiotherapy, ORIOLE trial, STOMP trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Journal of clinical oncology publication entitled Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials . The authors use two independent phase II trials, each of which enrolled men with…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Sustained benefit to metastasis-directed therapy vs observation: A pooled analysis of the #STOMP and #ORIOLE trials. @WallisCJD @UofT & @zklaassen_md @GACancerCenter join in this #JournalClub discussion on UroToday > https://t.co/5vRNjg4hAa @JCO_ASCO https://t.co/oyUOc1BFrv
-
-
Mashup Score: 3
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the second part of our interview with Dr. Matthew Deek (@matthewdeek) from @RutgersCancer, he shares with us how #PSMA imaging was used during the #ORIOLE trial to find areas of prostate cancer in patients. Watch the interview here: https://t.co/FyOTDPGDGb https://t.co/Wf31jLwNHx
-
-
Mashup Score: 0
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Journal of clinical oncology publication entitled Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials . The authors use two independent phase II trials, each of which enrolled men with…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Sustained benefit to metastasis-directed therapy vs observation: A pooled analysis of the #STOMP and #ORIOLE trials. @WallisCJD @UofT & @zklaassen_md @GACancerCenter join in this #JournalClub discussion on UroToday > https://t.co/5vRNjg4hAa @JCO_ASCO https://t.co/IzUjSsrtTq
-
-
Mashup Score: 1
metastatic castration-resistant prostate cancer (mCRPC), STOMP trial, ORIOLE trial, genetic biomarkers prostate cancer, oligometastatic castration-sensitive prostate cancer, androgen deprivation (ADT) free survival, stereotactic ablative radiation (SABR).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes and genetic predictors of response to metastasis-directed therapy vs observation in oligometastatic #ProstateCancer: analysis of #STOMP and #ORIOLE trials. #BeyondTheAbstract on UroToday > https://t.co/o03cyAfYwJ @matthewdeek @kim_vdeecken @piet_ost @JCO_ASCO https://t.co/24z8ww2wNO
-
-
Mashup Score: 2
metastatic castration-resistant prostate cancer (mCRPC), STOMP trial, ORIOLE trial, genetic biomarkers prostate cancer, oligometastatic castration-sensitive prostate cancer, androgen deprivation (ADT) free survival, stereotactic ablative radiation (SABR).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes and genetic predictors of response to metastasis-directed therapy vs observation in oligometastatic #ProstateCancer: analysis of #STOMP and #ORIOLE trials. #BeyondTheAbstract on UroToday > https://t.co/o03cyAfqHb @matthewdeek @kim_vdeecken @piet_ost @JCO_ASCO https://t.co/33PKkU32AF
-
-
Mashup Score: 1
metastatic castration-resistant prostate cancer (mCRPC), STOMP trial, ORIOLE trial, genetic biomarkers prostate cancer, oligometastatic castration-sensitive prostate cancer, androgen deprivation (ADT) free survival, stereotactic ablative radiation (SABR).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes and genetic predictors of response to metastasis-directed therapy vs observation in oligometastatic #ProstateCancer: analysis of #STOMP and #ORIOLE trials. #BeyondTheAbstract on UroToday > https://t.co/o03cyAfqHb @matthewdeek @kim_vdeecken @piet_ost @JCO_ASCO https://t.co/mvIMqRvlpu
-
-
Mashup Score: 0
ESMO 2022 Long-term outcomes of STOMP and ORIOLE, stereotactic ablative radiation versus observation in metachronous oligometastatic castration-sensitive prostate cancer, analysis of genomic predictors of response.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term outcomes from the #STOMP and #ORIOLE trials suggest a sustained clinical benefit to metastasis-directed treatment over observation in oligometastatic castration-sensitive #ProstateCancer. #ReadNow details on UroToday > https://t.co/sKOiF8hRro @JCO_ASCO @HopkinsMedicine https://t.co/3jVWVdBpLF
-
-
Mashup Score: 1
ASCO 2022 pooled analysis of the STOMP and ORIOLE trials examining long-term outcomes and genetic predictors of response to metastasis directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer.
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
Long-term outcomes and genetic predictors of response to metastasis-directed therapy vs observation in oligometastatic castration-sensitive #ProstateCancer: A pooled analysis of #STOMP and #ORIOLE trials @matthewdeek @RutgersCancer. #ASCO22 > https://t.co/OyJNAOIzl8 @WallisCJD https://t.co/r1iUtkSg8p
-
-
Mashup Score: 1The ORIOLE Trial Results Discussed: Outcomes of Observation vs SABR for Oligometastatic Prostate Cancer - Phuoc T. Tran - 4 year(s) ago
The ORIOLE Phase 2 Randomized Clinical Trial set out to answer the question, “how effectively does stereotactic ablative radiotherapy prevent progression of disease compared with observation in men with recurrent hormone-sensitive prostate cancer with 1 to 3 metastases?” Dr. Tran joins Alicia Morgans and discusses this phase 2 randomized clinical trial of 54 men, where the progression of…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
The #ORIOLE trial - stereotactic ablative radiotherapy a promising treatment approach for men with recurrent hormone-sensitive oligometastatic #prostatecancer. #ListenNow > https://t.co/NPlt3JUpQt Phuoc Tho Tran, MD, PhD @HopkinsMedicine @CaPsurvivorship @NUFeinbergMed https://t.co/SpMt5hvcs6
-
PSMA-positive extracellular vesicles predict disease recurrence in oligometastatic castration-sensitive #ProstateCancer treated with SBRT: analysis of the #ORIOLE trial. Presented by Edlira Horjeti, MD @MayoClinic. #ASTRO23 coverage by @zklaassen_md > https://t.co/Sl5ODGbAIV https://t.co/EUIdNdw7yj